Previous 10 | Next 10 |
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly to Charles M. Baum, M.D., Ph.D., President and Chief ...
Mirati Therapeutics Inc. ( MRTX ) stock has seen quite some interest in recent times, especially after Amgen (AMGN) reported preclinical data from the study of their KRAS G12C inhibitor drug AMG 510. However, this is not its lead candidate, and we don't gauge companies by looking at molecules ...
Mirati Therapeutics (NASDAQ: MRTX ): Q2 GAAP EPS of -$1.26. More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019 . Second Quarter Highlights: Initiated the Phase 3 randomized clinical trial, ...
Stericycle (NASDAQ: SRCL ) upgraded to Neutral with a $44 (flat) price target at Baird. More news on: Stericycle, Inc., Abiomed, Inc., Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...
Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...
Mirati Therapeutics ( MRTX ) announced that it had formed a collaboration agreement with Novartis ( NVS ) to target patients with advanced solid tumors. This clinical combination is expected to go after a particular subset of the market dealing with solid tumors in a couple of cancer typ...
Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up 11% premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...
SAN DIEGO , July 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO...
Editor's note: Seeking Alpha is proud to welcome PylBio Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Welcome to ou...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...